The company that manufactures belimumab is GlaxoSmithKline (GSK) [1]. Belimumab is marketed under the brand name Benlysta [2].
What is belimumab used to treat?
Belimumab is approved for the treatment of active systemic lupus erythematosus (SLE) in adult patients who are receiving standard therapy [3]. It is also indicated for active lupus nephritis in adult patients and active childhood lupus in patients aged 5 years and older [4].
When did belimumab receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved belimumab for the treatment of systemic lupus erythematosus in March 2011 [3]. Approval for active lupus nephritis followed in December 2020 [4].
How does belimumab work?
Belimumab is a biologic medication that works by targeting B-lymphocyte stimulator (BLyS), a protein that plays a role in the survival of B cells [5]. By binding to BLyS, belimumab prevents it from binding to its receptors on B cells, thereby reducing the number of B cells that mature into plasma cells, which produce antibodies [5]. This mechanism helps to reduce autoantibody production in patients with lupus [5].
Are there any patent expirations for belimumab?
Information regarding belimumab's patent status and potential expirations can be found on DrugPatentWatch.com [6]. Patent timelines are critical for understanding when generic or biosimilar versions of a drug may become available.
What are the side effects of belimumab?
Common side effects of belimumab can include nausea, diarrhea, fever, rash, pain in the arms or legs, and insomnia [4]. More serious side effects may include serious infections, depression, and an increased risk of certain cancers [4]. Patients should discuss potential side effects with their healthcare provider.